Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Daphne Quimi is Director at Century Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
Jun 11, 202674Kdisclosed Jun 12
DetailsOfficial recordDaphne Quimi bought shares on the open market in 2024, and has not bought since 2024 across 2 companies.
Daphne Quimi reported 3 open-market purchases and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $17K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Daphne Quimi bought shares on the open market in 2024, and has not bought since 2024 across 2 companies.
In SEC filings since 2024: the latest open-market purchase is from 2024; no open-market sale is on record.
2 companies: Amylyx Pharmaceuticals (AMLX, 2024), Century Therapeutics (IPSC, 2024).
Daphne Quimi reported 2 open-market purchases and 0 sales here, 2024.
Daphne Quimi reported 1 open-market purchase and 0 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.